Every protocol decision affects patients, and only those with lived disease experience can identify true burden — from invasive biopsies to daily trial demands.
|Articles|August 27, 2015
Novo Nordisk to Start Phase III Trial for Oral Biologic
Author(s)Randi Hernandez
August 27, 2015.
Advertisement
Novo Nordisk has big plans for its diabetes franchise. Yesterday the company announced that it would begin Phase IIIa trials for oral semaglutide, a protein product that can be administered orally, rather than via injection. In the first trial of the program-which is slated to begin in 2016-doses of 3 mg, 7 mg, and 14 mg of the long-acting glucagon-like peptide-1 (GLP-1) analog will be compared with a 100-mg dose of sitagliptin, another oral diabetes medication. The other parts of the program will roll out during 2016 as well.
Advertisement
Related to this article
With 60% of Americans using AI health tools, patient advocates are encouraging collaborative use of AI alongside healthcare teams for better outcomes.
AI can make clinical trials smarter and faster, but lived patient experience remains irreplaceable in guiding research toward optimal results.
AstraZeneca acquires Omniose, to bolster it's preclinical infectious disease programs.
AI can make clinical trials smarter and faster, but lived patient experience remains irreplaceable in guiding research toward optimal results.
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly Breaks Ground on $3.5 billion Pennsylvania Manufacturing Site
2
Moderna Lays Out Oncology-Driven Growth Plan at 2026 Analyst Day
3
Pfizer and Blackstone Sign Co-Funding Deal for berobenatide
4
FDA Pauses Commissioner’s National Priority Voucher Program: Report
5